Article Text

Download PDFPDF
Is ATP7B a Predictive Marker in Patients With Ovarian Carcinoma Treated With Platinum-Taxane Combination Chemotherapy?
  1. Hiroshi Katagiri, MD*,
  2. Kentaro Nakayama, MD, PhD*,
  3. Mohammed Tanjimur Rahman, MBBS*,
  4. Munmun Rahman, MBBS*,
  5. Atsuko Katagiri, MD*,
  6. Tomoka Ishibashi, MD*,
  7. Masako Ishikawa, MD, PhD*,
  8. Kouji Iida, BSc*,
  9. Satoru Nakayama, MD,
  10. Yoshiro Otsuki, MD and
  11. Kohji Miyazaki, MD, PhD*
  1. *Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Japan;
  2. Department of Obstetrics and Gynecology, and
  3. Department of Pathology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
  1. Address correspondence and reprint requests to Kentaro Nakayama, MD, PhD, Department of Obstetrics and Gynecology, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane, Japan 6938501. E-mail: kn88{at}med.shimane-u.ac.jp.

Abstract

Objective This study examined the prognostic significance of copper-transporting P-type adenosine triphosphatase (ATP7B) expression in patients with ovarian carcinoma treated with platinum-taxane combination chemotherapy.

Methods Expression of ATP7B in ovarian carcinoma was assessed by immunohistochemistry and clinical data collected by retrospective review of medical charts.

Results Overexpression of ATP7B was identified in 25 (29.1%) of 86 ovarian carcinomas. The frequency of ATP7B expression in clear cell carcinomas was significantly higher than that in serous high-grade carcinomas (P < 0.05). We observed no statistically significant correlations between high ATP7B protein expression and either disease-free survival (P = 0.722) or overall survival (P = 0.389).

Conclusions Our study is the first to demonstrate a lack of statistically significant differences between ATP7B positive and negative cases with respect to prognosis of patients with ovarian carcinoma treated with a platinum-taxane combination regimen. However, that ATP7B expression in clear cell carcinomas was significantly higher than that in serous carcinomas may partially explain the difference in chemotherapeutic response and prognosis between patients with these 2 types of carcinomas.

  • Ovarian carcinoma
  • Clear cell carcinoma
  • ATP7B
  • Survival
  • Platinum
  • Taxane

Statistics from Altmetric.com

Footnotes

  • This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology in Japan, Suzuken Memorial Foundation, and Takeda Science Foundation.

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.